Drug Profile
Research programme: prostate cancer therapeutics - Avantogen Oncology
Alternative Names: BIO 133Latest Information Update: 16 Mar 2009
Price :
$50
*
At a glance
- Originator Avantogen Oncology
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 01 Jun 2006 Innovate Oncology is now a wholly owned subsidiary of Avantogen
- 30 May 2006 Innovate Oncology has been acquired by Avantogen
- 16 Sep 2005 Preclinical trials in Prostate cancer in USA (unspecified route)